Matthew Goetz

Dec 9, 2024 | jamanetwork.com | Ashley K Saito |Matthew Goetz |Simon Wu

When Can a MRSA Nares Swab Guide Antibiotic Stewardship?What the Nose Knows Clinicians treating infections in the hospital often face uncertainty about when coverage for methicillin-resistant Staphylococcus aureus (MRSA) is warranted.

Apr 25, 2024 | nature.com | Matthew Goetz |Sara M. Tolaney |Valentina Guarneri |Miguel Cabral Martin |Miguel Martín |Nadia Harbeck | +1 more

AbstractIn monarchE, adjuvant abemaciclib significantly improved invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), with sustained benefit beyond the 2-year treatment period. Abemaciclib dose reductions were allowed to proactively manage adverse events. Exploratory analyses to investigate the impact of dose reductions on efficacy were conducted.

Apr 11, 2024 | onclive.com | Matthew Goetz

Matthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses pharmacokinetic data for neoadjuvant (Z)-endoxifen derived from the phase 2 EVANGELINE trial (NCT05607004) of premenopausal patients with metastatic estrogen receptor (ER)–positive, HER2-negative breast cancer.

Aug 25, 2023 | onclive.com | Matthew Goetz

Matthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the available treatment options for patients with metastatic hormone receptor (HR)–positive breast cancer in the post-CDK inhibitor setting. The treatment armamentarium for patients with HR-positive breast cancer whose disease has progressed following prior treatment with a CDK4/6 inhibitor has greatly expanded in recent years, Goetz begins.